Strukturelle Veränderungen des Herzens bei Patienten mit chronischer Nierenerkrankung

Zusammenfassung

In Deutschland sind ca. 8–10 Millionen Menschen von chronischer Nierenkrankheit (CKD) betroffen, wobei von einer hohen Dunkelziffer auszugehen ist, da die CKD vor allem im Frühstadium nicht immer richtig erkannt wird. Die CKD, die hauptsächlich durch kardiovaskuläre Risikofaktoren wie Diabetes mellitus (DM) und arterielle Hypertonie (HAT) verursacht wird, kann im Verlauf erhebliche Auswirkungen auf das Herz haben und zu strukturellen Veränderungen wie linksventrikulärer Hypertrophie (LVH), Kalzifizierung, Fibrosierung und diastolischer Dysfunktion führen. Diese Veränderungen können in einem Teufelskreis das Fortschreiten der CKD begünstigen, indem sie schwere Klappenvitien verursachen, die zu einer Reduktion der systolischen Funktion führen können, was wiederum das Volumenmanagement erheblich erschweren kann. Diagnostische Verfahren wie die Echokardiografie oder die Magnetresonanztomografie können hier wichtige Informationen zur Erkennung dieser Veränderungen liefern. Wie immer in der Medizin ist Vorbeugung die beste Therapie. Daher müssen wir Ärzte beide Organe und ihre Wechselwirkungen genau verstehen, um rechtzeitig und richtig eingreifen zu können. In diesem Rahmen sind kardionephrologische Konferenzen für einen besseren Wissensaustausch und eine bessere Therapie notwendig.

Publication History

Article published online:
20 March 2025

• Literatur

• 1 Mahmood SS, Levy D, Vasan RS. et al. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet 2014; 383: 999-1008
• 2 Denker M, Boyle S, Anderson AH. et al. Chronic Renal Insufficiency Cohort Study (CRIC): Overview and Summary of Selected Findings. Clin J Am Soc Nephrol 2015; 10: 2073-2083
• 3 Grams ME, Coresh J, Matsushita K. et al. Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis. Jama 2023; 330: 1266-1277
• 4 Ronco C, Haapio M, House AA. et al. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527-1539
• 5 Park M, Shlipak MG, Katz R. et al. Subclinical cardiac abnormalities and kidney function decline: the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol 2012; 7: 1137-1144
• 6 London GM. Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial 2003; 16: 85-94
• 7 Foley RN, Parfrey PS, Harnett JD. et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-192
• 8 Nadruz W. Myocardial remodeling in hypertension. J Hum Hypertens 2015; 29: 1-6
• 9 Ritz E. Left ventricular hypertrophy in renal disease: beyond preload and afterload. Kidney Int 2009; 75: 771-773
• 10 Ma K, Gao W, Xu H. et al. Role and Mechanism of the Renin-Angiotensin-Aldosterone System in the Onset and Development of Cardiorenal Syndrome. J Renin Angiotensin Aldosterone Syst 2022; 2022: 3239057
• 11 Fountain JH, Kaur J, Lappin SL. Physiology, Renin Angiotensin System. [Updated 2023 Mar 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Im Internet: Accessed December 10, 2024 at: https://www.ncbi.nlm.nih.gov/books/NBK470410/
• 12 Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 292: C82-C97
• 13 Vink EE, de Jager RL, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease: pathophysiology and (new) treatment options. Curr Hypertens Rep 2013; 15: 95-101
• 14 Wang Y, Seto SW, Golledge J. Angiotensin II, sympathetic nerve activity and chronic heart failure. Heart Fail Rev 2014; 19: 187-198
• 15 Schlaich MP, Sobotka PA, Krum H. et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361: 932-934
• 16 Campese VM, Romoff MS, Levitan D. et al. Mechanisms of autonomic nervous system dysfunction in uremia. Kidney Int 1981; 20: 246-253
• 17 Tust M, Müller JP, Fischer D. et al. SLC22A11 Inserts the Uremic Toxins Indoxyl Sulfate and P-Cresol Sulfate into the Plasma Membrane. Int J Mol Sci 2023; 24: 15187
• 18 Lee BT, Ahmed FA, Hamm LL. et al. Association of C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease. BMC Nephrol 2015; 16: 77
• 19 Kaur J, Young BE, Fadel PJ. Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms. Int J Mol Sci 2017; 18: 1682
• 20 Dube P, DeRiso A, Patel M. et al. Vascular Calcification in Chronic Kidney Disease: Diversity in the Vessel Wall. Biomedicines 2021; 9: 404
• 21 Schlieper G, Schurgers L, Brandenburg V. et al. Vascular calcification in chronic kidney disease: an update. Nephrol Dial Transplant 2016; 31: 31-39
• 22 Inserra F, Forcada P, Castellaro A. et al. Chronic Kidney Disease and Arterial Stiffness: A Two-Way Path. Front Med (Lausanne) 2021; 8: 765924
• 23 Zanoli L, Lentini P, Briet M. et al. Arterial Stiffness in the Heart Disease of CKD. J Am Soc Nephrol 2019; 30: 918-928
• 24 Maher ER, Young G, Smyth-Walsh B. et al. Aortic and mitral valve calcification in patients with end-stage renal disease. Lancet 1987; 2: 875-877
• 25 Ternacle J, Côté N, Krapf L. et al. Chronic Kidney Disease and the Pathophysiology of Valvular Heart Disease. Can J Cardiol 2019; 35: 1195-1207
• 26 Bai J, Zhang X, Zhang A. et al. Cardiac valve calcification is associated with mortality in hemodialysis patients: a retrospective cohort study. BMC Nephrol 2022; 23: 43
• 27 Hahn J, Virk HUH, Al-Azzam F. et al. Outcomes of Transcatheter Aortic Valve Implantation in Patients With Chronic and End-Stage Kidney Disease. Am J Cardiol 2022; 164: 100-102
• 28 López B, Ravassa S, Moreno MU. et al. Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches. Nat Rev Cardiol 2021; 18: 479-498
• 29 Mondal NK, Walther CP. Insights into Myocardial Fibrosis in Advanced Chronic Kidney Disease Using Human Tissue. Kidney360 2023; 4: 1531-1533
• 30 Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol 2009; 4 (Suppl. 1) S79-S91
• 31 Grant AD, Negishi K, Negishi T. et al. Grading diastolic function by echocardiography: hemodynamic validation of existing guidelines. Cardiovasc Ultrasound 2015; 13: 28
• 32 Sohns C, Marrouche NF. Atrial fibrillation and cardiac fibrosis. Eur Heart J 2020; 41: 1123-1131
• 33 Morita N, Mandel WJ, Kobayashi Y. et al. Cardiac fibrosis as a determinant of ventricular tachyarrhythmias. J Arrhythm 2014; 30: 389-394
• 34 Jankowski J, Floege J, Fliser D. et al. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation 2021; 143: 1157-1172
• 35 Nardi E, Mulè G, Giammanco A. et al. Left ventricular hypertrophy in chronic kidney disease: A diagnostic criteria comparison. Nutr Metab Cardiovasc Dis 2021; 31: 137-144
• 36 Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141: 334-341
• 37 Bonagura JD, Blissitt KJ. Echocardiography. Equine Vet J Suppl 1995; 5–17
• 38 Senior R, Becher H, Monaghan M. et al. Contrast echocardiography: evidence-based recommendations by European Association of Echocardiography. Eur J Echocardiogr 2009; 10: 194-212
• 39 Flachskampf FA, Wouters PF, Edvardsen T. et al. Recommendations for transoesophageal echocardiography: EACVI update 2014. Eur Heart J Cardiovasc Imaging 2014; 15: 353-365
• 40 Busse A, Rajagopal R, Yücel S. et al. Cardiac MRI-Update 2020. Radiologe 2020; 60: 33-40
• 41 Weinmann HJ, Brasch RC, Press WR. et al. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. AJR Am J Roentgenol 1984; 142: 619-624
• 42 Mewton N, Liu CY, Croisille P. et al. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol 2011; 57: 891-903
• 43 Aquaro GD, De Gori C, Faggioni L. et al. Diagnostic and prognostic role of late gadolinium enhancement in cardiomyopathies. Eur Heart J Suppl 2023; 25: C130-C136
• 44 Starekova J, Pirasteh A, Reeder SB. Update on Gadolinium-Based Contrast Agent Safety, From the AJR Special Series on Contrast Media. AJR Am J Roentgenol 2024; 223: e2330036